

Oxaprozin

Catalog No: tcsc7975



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

21256-18-8

Formula:

$C_{18}H_{15}NO_3$

Pathway:

Immunology/Inflammation;NF-κB

Target:

COX;NF-κB

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (340.92 mM)

Alternative Names:

Oxaprozinum;Wy21743

Observed Molecular Weight:


293.32

Product Description

Oxaprozin is an inhibitor of both **COX-1** and **COX-2** with **IC₅₀**s of 2.2 μ M and 36 μ M for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of **NF- κ B**.

IC50 & Target: IC50: 2.2 μ M (COX-1), 36 μ M (COX-2) \square NF- κ B^[1]

In Vitro: Oxaprozin induces apoptosis in a dose-dependent manner. Oxaprozin increases caspase-3 activity in the activated but not in the resting condition. NF- κ B activation is inhibited by 50 μ M Oxaprozin. Oxaprozin inhibits activation of the IKK system induced by the reagent I κ B α ^[1]. Oxaprozin dose dependently increase CD40L-treated monocyte apoptosis. 100 μ M Oxaprozin induces the strongest proapoptotic effect. 100 μ M Oxaprozin significantly increases CD40L-treated monocyte apoptosis. Oxaprozin treatment inhibits CD40L-induced Akt and NF- κ B (p65) phosphorylation^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!